These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36852326)

  • 1. P16
    Sun J; Zhou L; Yang T; Deng B; Bao Y; Gu L; Wang H; Wang L
    Oxid Med Cell Longev; 2023; 2023():1696190. PubMed ID: 36852326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockout of Canopy 2 activates p16
    Yin W; Guo J; Zhang C; Alibhai FJ; Li SH; Billia P; Wu J; Yau TM; Weisel RD; Li RK
    J Mol Cell Cardiol; 2019 Jul; 132():36-48. PubMed ID: 31047986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.
    McConnell BB; Gregory FJ; Stott FJ; Hara E; Peters G
    Mol Cell Biol; 1999 Mar; 19(3):1981-9. PubMed ID: 10022885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
    Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
    Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of p16
    Khatiwala RV; Zhang S; Li X; Devejian N; Bennett E; Cai C
    Stem Cell Rev Rep; 2018 Aug; 14(4):612-625. PubMed ID: 29675777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
    Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
    Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactive oxygen species promotes cellular senescence in normal human epidermal keratinocytes through epigenetic regulation of p16(INK4a.).
    Sasaki M; Kajiya H; Ozeki S; Okabe K; Ikebe T
    Biochem Biophys Res Commun; 2014 Sep; 452(3):622-8. PubMed ID: 25181340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of CDK7-carboxyl-terminal domain kinase activity by the tumor suppressor p16(INK4A) contributes to cell cycle regulation.
    Nishiwaki E; Turner SL; Harju S; Miyazaki S; Kashiwagi M; Koh J; Serizawa H
    Mol Cell Biol; 2000 Oct; 20(20):7726-34. PubMed ID: 11003668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
    Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
    J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CREG1 enhances p16(INK4a) -induced cellular senescence.
    Moolmuang B; Tainsky MA
    Cell Cycle; 2011 Feb; 10(3):518-30. PubMed ID: 21263217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53.
    Chien WW; Domenech C; Catallo R; Salles G; Ffrench M
    Cell Cycle; 2010 Aug; 9(16):3286-96. PubMed ID: 20703084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component.
    Xu G; Li JY
    J Neurooncol; 2018 Feb; 136(3):445-452. PubMed ID: 29150788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations.
    Villacañas O; Pérez JJ; Rubio-Martínez J
    J Biomol Struct Dyn; 2002 Dec; 20(3):347-58. PubMed ID: 12437373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms.
    Ruas M; Gregory F; Jones R; Poolman R; Starborg M; Rowe J; Brookes S; Peters G
    Mol Cell Biol; 2007 Jun; 27(12):4273-82. PubMed ID: 17420273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting p16
    Zysman M; Baptista BR; Essari LA; Taghizadeh S; Thibault de Ménonville C; Giffard C; Issa A; Franco-Montoya ML; Breau M; Souktani R; Aissat A; Caeymaex L; Lizé M; Van Nhieu JT; Jung C; Rottier R; Cruzeiro MD; Adnot S; Epaud R; Chabot F; Lanone S; Boczkowski J; Boyer L
    Am J Respir Crit Care Med; 2020 Oct; 202(8):1088-1104. PubMed ID: 32628504
    [No Abstract]   [Full Text] [Related]  

  • 16. INK4a deletion results in improved kidney regeneration and decreased capillary rarefaction after ischemia-reperfusion injury.
    Lee DH; Wolstein JM; Pudasaini B; Plotkin M
    Am J Physiol Renal Physiol; 2012 Jan; 302(1):F183-91. PubMed ID: 21957175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p16INK4a-induced senescence is disabled by melanoma-associated mutations.
    Haferkamp S; Becker TM; Scurr LL; Kefford RF; Rizos H
    Aging Cell; 2008 Oct; 7(5):733-45. PubMed ID: 18843795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression.
    Ausserlechner MJ; Obexer P; Geley S; Kofler R
    Leukemia; 2005 Jun; 19(6):1051-7. PubMed ID: 15800668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p16( INK4a) positively regulates cyclin D1 and E2F1 through negative control of AUF1.
    Al-Khalaf HH; Colak D; Al-Saif M; Al-Bakheet A; Hendrayani SF; Al-Yousef N; Kaya N; Khabar KS; Aboussekhra A
    PLoS One; 2011; 6(7):e21111. PubMed ID: 21799732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK redundancy guarantees cell cycle progression in Rb-negative tumor cells independently of their p16 status.
    Santamariña M; Hernández G; Zalvide J
    Cell Cycle; 2008 Jul; 7(13):1962-72. PubMed ID: 18604173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.